Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep announces complete recruitment of initial NSCLC cohort (ASX:IMM)

Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients for TACTI-002 Trial Recruitment for 2nd line (PD-1 refractory) NSCLC and 2nd line HNSCC cohorts of the TACTI-002 tr...read more

Immutep announces First patient dosed in INSIGHT-004 (ASX:IMM)

Highlights First patient received first dose in INSIGHT-004, a phase I clinical trial Evaluates the combination of eftilagimod alpha with avelumab (BAVENCIO®) in different cancer i...read more

Imugene announces Updated Phase 1b HER-Vaxx data presented at ASCO (ASX:IMU)

SYDNEY, Australia, 4 June 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced positive data from the ongoing patients in the Phase Ib study of its HER-Vaxx cance...read more

Imugene announces Updated Phase Ib HER-Vaxx data (ASX:IMU)

Immutep announces Appendix 3B (ASX:IMM)

Appendix 3B New issue announcement, application for quotation of additional securities and agreement and agreement For further information please download PDF attached:

Immutep Announces Poster Presentation at ASCO (ASX:IMM)

SYDNEY, AUSTRALIA – 3 June 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy...read more

Immutep granted European patent for eftilagimod alpha (ASX:IMM)

SYDNEY, AUSTRALIA – 23 May 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treat...read more

Imugene announce Global Biotechnology and Venture Capital Executive Joins Imugene Board (ASX:IMU)

SYDNEY Australia 20 May 2019: The Board of Imugene Limited today announced the appointment of leading biotechnology executive and entrepreneur Dr Jens Eckstein as a Non-Executive Director, effective 2...read more

Immutep announces More mature positive data for TACTI-mel trial presented (ASX:IMM)

SYDNEY, AUSTRALIA – May 17, 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy trea...read more

Immutep to present at upcoming industry conferences (ASX:IMM)

SYDNEY, AUSTRALIA – May 10, 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy trea...read more

Immutep, Form 603 (ASX:IMM)

Notice of initial substantial holder To view Notice please download PDF attached:

Immutep, Operational Update (ASX:IMM)

Highlights - Recruitment for the AIPAC study expected to be completed in Q2 2019 - 15 patients enrolled in TACTI-002 Phase II collaboration study with MSD - Trial protocol approved for the IN...read more

Imugene Announces New HER-Vaxx Cancer Vaccine Phase Ib trial data to be presented at the American Society of Clinical Oncology 2019 Annual Meeting (ASX:IMU)

SYDNEY, Australia, 29 April 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced updated data from the ongoing patients in the Phase Ib study of its HER-Vaxx canc...read more

Immutep, Appendix 4C (ASX:IMM)

Quarterly report for entities subject to Listing Rule 4.7B Quarter ended ("current quarter"): 31st March 2019 To view Report please download PDF attached: